1. Home
  2. EKSO vs PRPO Comparison

EKSO vs PRPO Comparison

Compare EKSO & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ekso Bionics Holdings Inc.

EKSO

Ekso Bionics Holdings Inc.

HOLD

Current Price

$11.38

Market Cap

37.9M

Sector

Health Care

ML Signal

HOLD

Logo Precipio Inc.

PRPO

Precipio Inc.

HOLD

Current Price

$28.15

Market Cap

44.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
EKSO
PRPO
Founded
2005
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
44.4M
IPO Year
2012
2000

Fundamental Metrics

Financial Performance
Metric
EKSO
PRPO
Price
$11.38
$28.15
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$9.50
N/A
AVG Volume (30 Days)
58.7K
12.3K
Earning Date
04-27-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
41.76
92.15
EPS
N/A
N/A
Revenue
N/A
$24,049,000.00
Revenue This Year
$81.23
N/A
Revenue Next Year
$7.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.77
52 Week Low
$0.23
$5.45
52 Week High
$13.50
$29.80

Technical Indicators

Market Signals
Indicator
EKSO
PRPO
Relative Strength Index (RSI) 60.12 54.87
Support Level $9.18 $22.96
Resistance Level $13.16 $28.76
Average True Range (ATR) 0.97 1.59
MACD 0.19 0.11
Stochastic Oscillator 94.07 72.44

Price Performance

Historical Comparison
EKSO
PRPO

About EKSO Ekso Bionics Holdings Inc.

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: